Effect of deodorant and antiperspirant use and presence or absence of axillary Hair on absorption of testosterone 2% solution applied to men's axillae - Abstract

INTRODUCTION: Testosterone 2% solution is applied to axillae and is indicated for testosterone replacement therapy in males deficient in endogenous testosterone.

AIM: This open-label crossover study evaluated the effect of deodorant/antiperspirant use and presence or absence of axillary hair on absorption of testosterone solution.

METHODS: Healthy males (N = 30; ≥50 years of age with baseline testosterone < 400 ng/dL) were randomized to one of four treatment sequences involving six treatments. Each treatment consisted of one 1.5-mL dose of testosterone 2% solution (30 mg of testosterone) applied to each axilla. Axillae were unshaved or shaved, and were untreated or pretreated with deodorant/antiperspirant.

MAIN OUTCOME MEASURES: Blood samples were taken over 72 hours after each dose for measuring serum testosterone concentrations.

RESULTS: Profiles of mean testosterone concentrations were similar across treatments. For all treatments, area under the concentration-time curve through 24 hours (AUC[0-24] ) and 72 hours (AUC[0-72] ), and maximum total testosterone concentration (Cmax ) were similar except for 15% lower Cmax when treatment was applied after deodorant/antiperspirant to shaved vs. unshaved axillae (least squares mean, 531 ng/dL vs. 626 ng/dL, respectively; P = 0.011). This difference is not considered clinically significant. The 95% confidence intervals for AUC(0-24) , AUC(0-72) , and Cmax fell within the traditional bioequivalence limits of 0.8 to 1.25. Incidence of treatment-emergent adverse events (TEAEs) was low (< 15%) in each treatment arm, and most TEAEs were mild.

CONCLUSIONS: Absorption of testosterone 2% solution was unaffected by use of deodorant/antiperspirant or by the presence or absence of axillary hair. Testosterone solution was generally well tolerated.

Written by:
Small DS, Ni X, Polzer P, Vart R, Satonin DK, Mitchell MI.   Are you the author?
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Reference: J Sex Med. 2014 Aug 14. Epub ahead of print.
doi: 10.1111/jsm.12658

PubMed Abstract
PMID: 25123988

UroToday.com Androgen Deficiency Section